Agoracom Blog Home

Posts Tagged ‘investment’

VIDEO – Valeo Pharma Agreement Supports $30M Annual Revenue Target From Blood Thinner Product Alone

Posted by AGORACOM-JC at 4:12 PM on Wednesday, October 13th, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.  

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.   

Q3 Highlights:  

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

In today’s announcement, Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada.

Highlighted by the following;

  • 2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
  • The 2 multi-year product listings commenced on October 1, 2021
  • The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario

The agreement above supports $30M annual revenue target From blood thinner product alone!

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q3-21 Revenue of $5.7 million, up 280% over Q3-20

Posted by AGORACOM-JC at 5:22 PM on Thursday, September 23rd, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The company recently released Q3 results and highlights:

·  Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.

·  Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.

·  Record 9 months revenues at $10.2 million , up 94%.

·  Private and public reimbursement coverage expanding for Redesca®

·  New corporate structure completed with full commercial activities ongoing for Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

VIDEO – Biomind Labs (BMND : NEO) Is Developing The Next Generation of Medicines For The 21st Century – The Pharmaceutical Side of Psychedelics

Posted by AGORACOM-JC at 4:40 PM on Wednesday, August 25th, 2021
Biomind Labs Inc. Completes Reverse Take-Over Transaction | Business Wire

Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.

Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics

THE PROBLEM

● Depression and anxiety cost the global economy US$ 1 trillion each year

  • ~ 20% of the world’s children and adolescents have a mental health condition
  • Suicide is the second leading cause of death among 15-29 year-olds
  • 13% rise in mental health conditions & substance use disorders in last decade (to 2017)
  • Mental health conditions now cause 1 in 5 years lived with disability

#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things

More than 80% of the global population prefers natural products as sources of new drug candidates …

and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals  – creating drug therapies that harness the medicinal power of natural psychedelic compounds

1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.

Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.

VIDEO – Valeo Pharma (VPH:CSE) Reported Record Q2 Revenue of $2.65M, CEO Expects Q3 To Increase More Than 50%

Posted by AGORACOM-JC at 12:23 PM on Monday, July 5th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

The smile on CEO Steve Saviuk says it all. The company recently released Q2 results and highlights:

  • Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter
  • Q3-21 revenues expected to increase by more than 50% over Q2-21
  • Redesca (blood thinner) launched in late Q2-21
  • Commercial shipments of the company’s asthma drugs commenced following national respiratory sales force deployment
  • Closed upsized $6.645 million debenture placement
  • Closed $11.5 million bought deal

As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.

Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.

AGORACOM Small Cap 60: Valeo $VPH $VPHIF Blood Clot Prevention Drug Approved By Ont Drug Plan, Other Provinces To Follow Suit $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 10:43 AM on Friday, May 7th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

VIDEO – Valeo Pharma $VPH $VPHIF Drug Projected To Add $30M / Year Revenue Gets Ontario Public Drug Coverage $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:22 PM on Thursday, April 29th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • 2020 net revenues of $7.5 million
  • 2021 is expected to double to $15 million
  • Commercializing Novartis Asthma Therapies In Canada
  • Closed $6.6 Million Financing With Insiders Taking ~ 40% 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-20% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $40,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-20% market share without one hell of a fight.  Saviuk agreed and gave the following 3 reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

More than just lip service, $VPH just announced that Redesca is now listed on the Ontario Public Drug Program, which means the government will cover its costs for all public use.  Moreover, $VPH expects additional Provinces to follow.   

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

Valeo Pharma $VPH $VPHIF Announces Commercial Launch of Redesca™ and Redesca HP™ $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:12 AM on Thursday, April 15th, 2021
  • Shipments have commenced across Canada
  • National sales coverage in full deployment through a dedicated key account managers team
  • Private and public reimbursement activities on target.

MONTREAL , April 15, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has commenced commercial shipments across Canada of Redesca™ and Redesca HP™, its low molecular weight heparin (“LMWH”) biosimilar.

“Making Redesca™ widely available in Canada is a key element  of our commercialization plans and we are pleased to have done so ahead of target. We continue to work on expanding both public and private reimbursement coverage across all provinces”, said Steve Saviuk , Valeo’s Chief Executive Officer. ” Redesca™ is the first of three transformative products that Valeo is launching this year and it will be accretive to second quarter revenues with increasing sales growth in the quarters to come.”

Commenting on the Redesca™ commercial launch, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “Redesca™ is now available for patients, both at retail pharmacies and hospitals. The combination of a strong and proven safety profile, a complete product line, a robust supply chain on top of material savings to payers, contributes to the compelling Redesca™ value proposition for patients, clinicians and healthcare systems. We look forward to realizing Redesca™’s full potential over the coming quarters”.

In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWH are also now increasingly used as a first line of defense tool in the fight against COVID-19. The World Health Organization’s (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.

About Redesca®, Redesca HP®

Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Else $BABY.ca $BABYF Signs Agreement to Expand into 159 Vitamin Cottage Stores Across 20 States $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:50 AM on Wednesday, April 14th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced that it will expand distribution of it Plant-Based Complete Nutrition for Toddlers into 159 Natural Grocers by Vitamin Cottage stores across 20 states as of May 2021

VANCOUVER, BC , April 14, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY.V) (OTCQX: BABYF) (FSE: 0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company , announces that it will expand distribution of it Plant-Based Complete Nutrition for Toddlers into 159 Natural Grocers by Vitamin Cottage stores across 20 states as of May 2021.

“Launching at Natural Grocers by Vitamin Cottage drives significant and strategic distribution for the brand. We are particularly excited by the alignment between this retailer and with our brand, both focusing on helping people through sustainable, organic nutrition solutions, said Hamutal Yitzhak , Else CEO and Co-Founder. “We are eager to bring real, organic and whole food-based, clean label solutions to families in this region,” she added.

About Natural Grocers by Vitamin Cottage

Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is one of the leading natural food grocers in the US, with 159 stores in 20 states west of the Mississippi river. Founded in 1955, Natural Grocers is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial colors, flavors, preservatives or sweeteners, or partially hydrogenated or hydrogenated oils. The Company sells only USDA certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers’ flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, safe, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers make informed health and nutrition choices.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Valeo Pharma $VPH $VPHIF Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, April 14th, 2021
  • Announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000
  • Valeo insiders participate for $2.6 million

MONTREAL , April 14, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the “Offering”).

Each Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 200 Class “A” share purchase warrants (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Class “A” Share of the Company (each, a “Share”) at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the “Closing Date”). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.

“We are appreciative of the continued support from insiders and investors close to the Company  in this placement”, said Steve Saviuk , Valeo’s Chief Executive Officer. “This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years”.

The net proceeds of the Offering will be used for working capital and general corporate purposes.

Closing of the Private Placement is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the CSE. The Company may pay finder’s fees on the non-insider portion of the Private Placement, in compliance with applicable securities laws. All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.

The issuance of Convertible Debentures to the insiders will be considered related party transactions within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the requirements of MI 61-101 in respect of any Insider Participation.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

Else $BABY.ca $BABYF to launch product rollout to “Big Y” stores in April $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:03 AM on Wednesday, April 7th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced that it will begin its Northeast rollout by mid April 2021 , through “Big Y” World Class Markets, out of Springfield Massachusetts
  • Else’s Plant-Based Nutrition for Toddlers will be available for purchase in all 71 Big Y grocery stores.

VANCOUVER, BC , April 7, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company , announces that it will begin its Northeast rollout by mid April 2021 , through “Big Y” World Class Markets, out of Springfield Massachusetts . Else’s Plant-Based Nutrition for Toddlers will be available for purchase in all 71 Big Y grocery stores.

“Launching with Big Y represents another exciting milestone for Else,” said Hamutal Yitzhak , Else CEO and Co-Founder. “The northeast population size is paramount to the growth of our brand. Big Y’s large-format shelves and health-minded shoppers represent an opening into the progressive New England customer-base. We are eager to bring real, whole food-based, clean label solutions to families in this region,” she added.

About Big Y

Big Y is one of the largest independently owned supermarket chains in New England , and it employs over 12,000 people. In 2020 Big Y was the 210th-largest private company in the United States , according to that year’s Forbes magazine “500 Largest Private Companies” list. As of October 2020 , Big Y operates 71 supermarkets in Massachusetts and Connecticut ; [1] [3] many of which are located in the metropolitan areas of Springfield , Worcester , Greater Boston , and Hartford . In addition to its traditional supermarkets, Big Y owns and operates two specialty markets: Table & Vine, a large specialty liquor and wine store in West Springfield ; and the Fresh Acres Market, a concept mixing an open-air-style farmers’ market with upscale food choices, in Springfield . Big Y also operated two standalone pharmacies in Springfield and Wilbraham before eventually folding them into the pharmacies located in its nearby stores.